Receive Updates
Triemthoprim-Sulfa-Resistant Klebsiella pneumoniae
Co-trimoxazole resistance is rising but remains lower than among related species
BACKGROUND
Klebsiella pneumoniae is a member of the Enterobacteriaceae family, which along with E. coli accounts for the vast majority of hospital- and community-acquired urinary tract infections (UTIs). It is also a frequent cause of nosocomial (health care–associated) bloodstream infections and community-acquired pneumonia among alcoholics.
Trimethoprim-sulfa (also known as co-trimoxazole or TMP-SMZ) is recommended as a first-line therapy for uncomplicated UTIs. However, when regional resistance exceeds 20%, drugs such as fluoroquinolones become the drug of choice, per official guidelines. These broad-spectrum drugs are not only more expensive but also facilitate the selection of antibiotic-resistant strains across species.
U.S. RESISTANCE IN THE GLOBAL CONTEXT
RESISTANCE BY U.S. CENSUS DIVISION, 1999-2010
